Hainan Huluwa Pharmaceutical Group Co. Ltd.SSE: 605199

Announcement on Expected Loss in Performance for 2025

Jan 31, 2026 · Issued by Hainan Huluwa Pharmaceutical Group Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · Jan 31, 2026

On 6ix: 6ix.com/news/announcement-on-expected-loss-in-performance-for-2025-157

Announcement on Expected Loss in Performance for 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Hainan Huluwa Pharmaceutical Group Co. Ltd. on 6ix

Earlier from Hainan Huluwa Pharmaceutical

Announcement on Providing Guarantee for Wholly-owned Subsidiary by Guangxi Weiwei Pharmaceutical Co., Ltd.Jan 30
Indicative Announcement on Upcoming Judicial Auction of Some Shares Held by Controlling ShareholderJan 21
Announcement on Obtaining Drug Registration Certificate for Levosalbutamol Hydrochloride Nebuliser SolutionJan 6
Announcement on Abnormal Fluctuations in Stock TradingJan 1
Announcement on Receiving Notice of Case Filing from China Securities Regulatory CommissionDec 29, 2025

Later from Hainan Huluwa Pharmaceutical

Announcement on Wholly-Owned Subsidiary Obtaining Drug Registration Certificate for Compound Polyethylene Glycol (3350) Electrolyte Oral SolutionFeb 7
Announcement on Obtaining the Drug Registration Certificate for Ipratropium Bromide Solution for InhalationFeb 25
Announcement on Progress in Judicial Auction of Some Shares Held by Controlling ShareholderMar 3
Announcement on Wholly-owned Subsidiary Obtaining Drug Registration Certificate for Ambroxol Hydrochloride Oral DropsMar 5
Announcement on Obtaining Drug Registration CertificateMar 21

All Hainan Huluwa Pharmaceutical news releases

Follow Hainan Huluwa Pharmaceutical into a list and get an email when it puts out news.

Follow Hainan Huluwa Pharmaceutical